Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of A4250 (Odevixibat) in Healthy Subjects
NCT02963077Phase 1Completed
- Sponsor
- Albireo Pharma
- Start
- Jul 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC), primary biliary cholangitis (PBC), Alagille syndrome (ALGS) and 1 more (14 arms), sponsored by Albireo Pharma. Primary endpoints: Time to Maximum Plasma Concentration at 24 hours, Maximum Plasma Concentration at 24 hours and 5 more. Started Jul 2013; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)primary biliary cholangitis (PBC)Alagille syndrome (ALGS)cholestatic liver disease (CLD)
Beyond the preview
Go deeper on NCT02963077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02963077.